|Day's Range||0.000000 - 0.000000|
|52 Week Range|
|PE Ratio (TTM)||0.69|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||1.00|
It's been a tough year so far for the genomic sequencing leader's stock. Are better days ahead?
Higher costs of revenue hurt the genomic sequencing company in the fourth quarter.
Gilead Sciences, Inc.'s (GILD) fourth-quarter earnings (including stock-based compensation expenses) of $2.38 per share.